The brokerage firm has raised the Price Target to $ 55 from a previous price target of $51.
Advertisement
AERI has been the subject of several other reports. Aerie Pharmaceuticals Inc was Initiated by Raymond James to “Strong Buy” on Sep 14, 2016.
Aerie Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Needham & Company. Finally, Cantor Fitzgerald assumed coverage on Aerie Pharmaceuticals in a research note on Thursday, June 2nd. They now have a United States dollars 50 price target on the stock. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $43.11. AERI’s 50-day average is $18.99 and its 200-day moving average is $16.58.
The move comes after 8 months positive chart setup for the $554.39 million company.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Wednesday, August 3rd. The California-based Partner Investment Management L.P. has invested 1.28% in the stock. Analyst’s mean target price for Avis Budget Group, Inc. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company has 0.10% insider ownership. They now own 26.15 million shares or 2.97% more from 25.39 million shares in 2016Q1. BlackRock Advisors LLC raised its position in shares of Aerie Pharmaceuticals by 15.0% in the second quarter.
Seagate Technology PLC (NASDAQ:STX) traded 7.71 Million shares on last trading day with closing price of $36.09.
Aerie Pharmaceuticals Inc opened for trading at $21.15 and hit $21.99 on the upside on Wednesday, eventually ending the session at $21.13, with a gain of 7.53% or 1.48 points.
The institutional sentiment increased to 1.67 in Q2 2016.
Advertisement
Foresite Capital Management Ii Llc holds 11.73% of its portfolio in Aerie Pharmaceuticals Inc for 975,285 shares. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) weekly performance is 4.63%. The Company’s lead drug candidate, NUPLAZID, is under development for the treatment of Parkinson’s disease psychosis (PDP). The Company’s primary product candidates triple-action Rhopressa and quadruple-action Roclatan are once-daily eye drops.
